Jones Day Advises GenScript Biotech Corporation on $423.8 million Initial Public Offering and Spin-off of Subsidiary Legend Biotech Corporation | Digital Conqueror

Jones Day Advises GenScript Biotech Corporation on $423.8 million Initial Public Offering and Spin-off of Subsidiary Legend Biotech Corporation

HONG KONG, CHINA – Media OutReach – 9 June 2020 – Jones
Day acted as the US and Hong Kong legal advisors of GenScript Biotech
Corporation (Hong Kong: 1548) (“GenScript Biotech”) in relation to its (a)
approximately US$423.8 million initial public offering of 18,425,000 American
depositary shares and spin-off listing of its subsidiary Legend Biotech
Corporation (NASDAQ: LEGN) (“Legend Biotech”) on the Nasdaq Global Select
Market and (b) approximately US$24 million purchase of ordinary shares of
Legend Biotech in a concurrent private placement of Legend Biotech.

 

GenScript
Biotech is a leading life sciences research and application service and product
provider that applies its proprietary technology to various fields from basic
life sciences research to transformational biomedical development, industrial
synthetic products and cell therapeutic solutions. Its cell therapy business is
being run under Legend Biotech that engages in the discovery and development of
novel cell therapies for oncology and other indications.

 

Legend
Biotech’s lead product candidate is a chimeric antigen receptor, or CAR, T cell
therapy for the treatment of multiple myeloma.

 

In
March 2020, Jones Day also acted for GenScript Biotech in relation to its
approximately US$160 million pre-IPO financing of Legend Biotech.

 

The
IPO and the concurrent private placement completed today (June 8, 2020). 

 

The
Jones Day team was led by Charles Chau (Hong Kong) and Alan Seem (Silicon
Valley), and included Donna Ko (Hong Kong), Chen Ye (Silicon Valley), Wenxing
Feng (Hong Kong), and Flora Lo  (Hong Kong).

 

The press release has more information https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0605/2020060501353.pdf.

News Source: MediaOutreach

0 Comments

No comments!

There are no comments yet, but you can be first to comment this article.

Leave reply

<